Equities research analysts expect Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to report $76.07 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The lowest sales estimate is $73.50 million and the highest is $77.90 million. Amphastar Pharmaceuticals posted sales of $60.40 million during the same quarter last year, which suggests a positive year over year growth rate of 25.9%. The firm is expected to report its next earnings results on Monday, March 11th.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year sales of $281.02 million for the current fiscal year, with estimates ranging from $278.40 million to $282.90 million. For the next fiscal year, analysts forecast that the company will report sales of $337.63 million, with estimates ranging from $299.30 million to $363.30 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The firm had revenue of $75.54 million for the quarter, compared to the consensus estimate of $76.84 million. During the same period in the prior year, the business posted $0.07 earnings per share. The company’s revenue for the quarter was up 30.5% on a year-over-year basis.

AMPH has been the topic of several recent analyst reports. BidaskClub downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 13th. Needham & Company LLC reduced their price target on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 10th. ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Wells Fargo & Co reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday, November 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $26.00 price target on shares of Amphastar Pharmaceuticals in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $23.60.

Shares of NASDAQ AMPH opened at $20.51 on Friday. The company has a current ratio of 2.02, a quick ratio of 1.34 and a debt-to-equity ratio of 0.10. Amphastar Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $21.65. The company has a market capitalization of $952.85 million, a PE ratio of 53.97 and a beta of 1.38.

In other Amphastar Pharmaceuticals news, SVP Yakob Liawatidewi sold 17,808 shares of the firm’s stock in a transaction on Friday, November 9th. The stock was sold at an average price of $20.97, for a total transaction of $373,433.76. Following the transaction, the senior vice president now directly owns 46,763 shares in the company, valued at approximately $980,620.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $20.23, for a total value of $101,150.00. Following the transaction, the director now owns 40,434 shares in the company, valued at $817,979.82. The disclosure for this sale can be found here. Insiders have sold a total of 105,575 shares of company stock worth $2,196,689 over the last 90 days. 31.50% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Piedmont Investment Advisors LLC purchased a new position in Amphastar Pharmaceuticals during the 2nd quarter worth $128,000. Meeder Asset Management Inc. boosted its position in Amphastar Pharmaceuticals by 259.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock valued at $160,000 after acquiring an additional 7,572 shares in the last quarter. SG Americas Securities LLC bought a new stake in Amphastar Pharmaceuticals during the 2nd quarter valued at $161,000. Nisa Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $221,000. Finally, Paloma Partners Management Co bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $223,000. Institutional investors own 44.12% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Read More: Depreciation

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.